Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bradykinin contributes to vasogenic edema in murine experimental cerebral malaria.

The Journal of clinical investigation·2026
Same author

Morphophysiological dynamics of the proximal post-testicular ducts in Crotalus durissus Linnaeus, 1758 (Squamata: Viperidae).

Anatomical record (Hoboken, N.J. : 2007)·2026
Same author

Protocol for Standardized Assessment of Systemic Microvascular Function in Human Cutaneous Microcirculation Using Laser Speckle Contrast Imaging.

Journal of visualized experiments : JoVE·2026
Same author

Physicochemical Characterization of Anionic Lipid Membranes under Low and Physiological Ionic Strength: Effects of Moxifloxacin Assessed by Calorimetry, Spin-Label, Steady-State, and Time-Resolved Fluorescence.

ACS omega·2026
Same author

DHA-loaded nanocapsules enhance microcirculation and reduce inflammation in sepsis experimental model.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Exercise-induced esterified cholesterol transfer to HDL is enhanced in master endurance-trained athletes after moderate-intensity cycling.

Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme·2026

Related Experiment Video

Updated: Apr 18, 2026

In Vivo Tracking of Edema Development and Microvascular Pathology in a Model of Experimental Cerebral Malaria Using Magnetic Resonance Imaging
09:04

In Vivo Tracking of Edema Development and Microvascular Pathology in a Model of Experimental Cerebral Malaria Using Magnetic Resonance Imaging

Published on: June 8, 2017

7.0K

Lipoxin A4 attenuates endothelial dysfunction during experimental cerebral malaria.

Mariana C Souza1, Tatiana A Pádua1, Natália D Torres1

  • 1Laboratory of Applied Pharmacology, Farmanguinhos, Oswaldo Cruz Foundation, Rio de Janeiro, RJ, Brazil; National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.

International Immunopharmacology
|January 11, 2015
PubMed
Summary

Lipoxin A4 (LXA4) treatment prevents brain-blood barrier breakdown and improves symptoms in experimental cerebral malaria by modulating ICAM-1 and HO-1 expression, offering a new therapeutic avenue.

Keywords:
Brain–blood barrier breakdownEndothelial dysfunctionLipoxinMalaria

More Related Videos

Author Spotlight: Enhancing Cerebral Ischemia Research with a Simplified Rat Model
03:37

Author Spotlight: Enhancing Cerebral Ischemia Research with a Simplified Rat Model

Published on: July 5, 2024

1.2K
The Application Of Permanent Middle Cerebral Artery Ligation in the Mouse
08:27

The Application Of Permanent Middle Cerebral Artery Ligation in the Mouse

Published on: July 25, 2011

20.3K

Related Experiment Videos

Last Updated: Apr 18, 2026

In Vivo Tracking of Edema Development and Microvascular Pathology in a Model of Experimental Cerebral Malaria Using Magnetic Resonance Imaging
09:04

In Vivo Tracking of Edema Development and Microvascular Pathology in a Model of Experimental Cerebral Malaria Using Magnetic Resonance Imaging

Published on: June 8, 2017

7.0K
Author Spotlight: Enhancing Cerebral Ischemia Research with a Simplified Rat Model
03:37

Author Spotlight: Enhancing Cerebral Ischemia Research with a Simplified Rat Model

Published on: July 5, 2024

1.2K
The Application Of Permanent Middle Cerebral Artery Ligation in the Mouse
08:27

The Application Of Permanent Middle Cerebral Artery Ligation in the Mouse

Published on: July 25, 2011

20.3K

Area of Science:

  • Neuroscience
  • Immunology
  • Vascular Biology

Background:

  • Cerebral malaria (CM) involves brain-blood barrier (BBB) breakdown due to endothelial dysfunction.
  • Lipoxins (LX), like LXA4, are specialized pro-resolving mediators known to reduce endothelial dysfunction.
  • Previous studies showed LXA4 prolongs survival in Plasmodium berghei-infected mice by inhibiting IL-12 and CD8(+)IFN-γ(+) T cells, but its effect on ECM-induced endothelial dysfunction was unclear.

Purpose of the Study:

  • To investigate the role of LXA4 in ameliorating endothelial dysfunction during experimental cerebral malaria (ECM).
  • To determine if LXA4 treatment affects BBB integrity, behavioral symptoms, and specific molecular markers in ECM.

Main Methods:

  • Treatment of Plasmodium berghei-infected mice with LXA4.
  • Assessment of BBB breakdown, behavioral symptoms, TNF-α production, and microcirculation (functional capillary density).
  • Histological analysis of brain sections for capillary congestion and ICAM-1 expression.
  • In vitro studies using endothelial cells stimulated with parasitized red blood cells (RBCs) to assess ICAM-1 and HO-1 expression.

Main Results:

  • LXA4 treatment prevented BBB breakdown and improved behavioral symptoms in infected mice.
  • LXA4 increased functional capillary density and reduced capillary congestion and ICAM-1 expression in the brain.
  • In vitro, LXA4 inhibited ICAM-1 expression on endothelial cells stimulated by Plasmodium-parasitized RBCs.
  • LXA4 restored reduced HO-1 expression and inhibited parasite-RBC adhesion to endothelial cells, an effect dependent on HO-1.

Conclusions:

  • LXA4 ameliorates endothelial dysfunction in experimental cerebral malaria.
  • LXA4 exerts its protective effects by modulating ICAM-1 and HO-1 expression in brain tissue.
  • LXA4 represents a potential therapeutic agent for managing endothelial dysfunction in cerebral malaria.